Skip to main content

Market Overview

Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

Share:
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates
  • Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women’s Cancer.
  • GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform.
  • OVATION 2 Study data now show R0 resections in 14 of 17 patients, or 82%, in the GEN-1 + Neoadjuvant Chemotherapy (NACT) arm, compared with seven of 12 patients, or 58%, in the NACT alone arm.
  • R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.
  • The company recently has enrolled approximately 40% of the anticipated 110 patients into the OVATION 2 Study. To date, 29 patients have had their interval debulking surgery.
  • Price Action: CLSN shares are up 1.5% at $1.4 in the premarket trading on the last check Thursday.
 

Related Articles (CLSN)

View Comments and Join the Discussion!

Posted-In: Ovarian CancerBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com